Clinical Trials | September 05, 2025
AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension
The medicine was well tolerated, with no unexpected safety issue
The medicine was well tolerated, with no unexpected safety issue
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
Brenntag Specialties will provide pharmaceutical manufacturers and biopharmaceutical companies with a reliable supply of high-purity, GMP-compliant acetates
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D
Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
Subscribe To Our Newsletter & Stay Updated
